Chiara Molinelli, Flavia Jacobs, Guilherme Nader-Marta, Roberto Borea, Graziana Scavone, Silvia Ottonello, Piero Fregatti, Cynthia Villarreal-Garza, Jyoti Bajpai, Hee Jeong Kim, Silvia Puglisi, Evandro de Azambuja, Matteo Lambertini
Around 90% of breast tumours are diagnosed in the early stage, with approximately 70% being hormone receptor-positive. The cornerstone of adjuvant therapy for early-stage hormone receptor-positive breast cancer is endocrine therapy, tailored according to disease stage, biological characteristics of the tumour, patient's comorbidities, preferences and age. In premenopausal patients with hormone receptor-positive breast cancer, ovarian function suppression is a key component of the adjuvant endocrine treatment in combination with an aromatase inhibitor or tamoxifen...
March 13, 2024: Current Treatment Options in Oncology